← Back to Search

Cancer Vaccine

Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine for Glioblastoma

Phase < 1
Waitlist Available
Led By Ian Parney
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial looks at the side effects of using a vaccine made from a person's white blood cells and tumor proteins from another person's glioblastoma tumor to treat patients with glioblastoma that has come back.

Eligible Conditions
  • Glioblastoma (GBM)
  • Glioblastoma
  • Gliosarcoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of significant toxicity, defined as a dose limiting toxicity (DLT) that is possibly, probably, or definitely related to treatment as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Secondary outcome measures
Clinical benefit rate
Duration of response
Feasibility
+4 more
Other outcome measures
Change in immunologic correlates

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (vaccine therapy)Experimental Treatment2 Interventions
Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5 of courses 2 and 3, and on day 1 of subsequent courses. Treatment with malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine repeats every 21 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
2013
Completed Early Phase 1
~50

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,933,133 Total Patients Enrolled
322 Trials studying Glioblastoma
23,095 Patients Enrolled for Glioblastoma
Mayo ClinicLead Sponsor
3,205 Previous Clinical Trials
3,766,764 Total Patients Enrolled
14 Trials studying Glioblastoma
779 Patients Enrolled for Glioblastoma
Ian ParneyPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
21 Total Patients Enrolled
1 Trials studying Glioblastoma
21 Patients Enrolled for Glioblastoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Vaccine Therapy in Treating Patients With Recurrent Glioblastoma
2013. "Vaccine Therapy in Treating Patients With Recurrent Glioblastoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03360708.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top